Relapsed small cell lung cancer (SCLC) patients have limited treatment options and poor outcomes. NGR-hTNF is a vascular-targeting agent, which increases intratumoral chemotherapy penetration and T-lymphocyte infiltration.
NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer
Novello, S;Capelletto, Enrica;
2018-01-01
Abstract
Relapsed small cell lung cancer (SCLC) patients have limited treatment options and poor outcomes. NGR-hTNF is a vascular-targeting agent, which increases intratumoral chemotherapy penetration and T-lymphocyte infiltration.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
NGR-hTNF and doxorubicin as second line treatment of patients with small cell lung cancer_.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
256.85 kB
Formato
Adobe PDF
|
256.85 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
